TY - JOUR
T1 - Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial
AU - Titone Lanza Di Scalea, Lucina
AU - Cascio, Antonio
AU - Colomba, Claudia
AU - Di Martino, Lucio
PY - 2001
Y1 - 2001
N2 - Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/day orally in 2 divided doses, or chloramphenicol, 50 mg/kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P=.047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF
AB - Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/day orally in 2 divided doses, or chloramphenicol, 50 mg/kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P=.047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF
KW - clarithromycin Mediterranean spotted fever
KW - clarithromycin Mediterranean spotted fever
UR - http://hdl.handle.net/10447/63391
M3 - Article
VL - 33
SP - 409
EP - 411
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
ER -